Claims
- 1. Npt2B present in other than its natural environment.
- 2. The Npt2B according to claim 1, wherein said Npt2B has an amino acid sequence substantially identical to the sequence of SEQ ID NO:01.
- 3. A fragment of the Npt2B according to claim 1.
- 4. A nucleic acid present in other than its natural environment, wherein said nucleic acid has a nucleotide sequence encoding Npt2B.
- 5. A nucleic acid according to claim 4, wherein said nucleic acid has a nucleic acid sequence that is substantially identical to the nucleotide sequence of SEQ ID NO:02.
- 6. A fragment of the nucleic acid according to claim 4.
- 7. An isolated nucleic acid or mimetic thereof that hybridizes under stringent conditions to the nucleic acid according to claim 4 or its complementary sequence.
- 8. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a nucleotide sequence found in the nucleic acid according to claim 4 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host.
- 9. A cell comprising an expression cassette according to claim 8 as part of an extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell.
- 10. The cellular progeny of the host cell according to claim 9.
- 11. A method of producing Npt2B, said method comprising: growing a cell according to claim 9, whereby said Npt2B is expressed; and isolating said Npt2B substantially free of other proteins.
- 12. A monoclonal antibody binding specifically to Npt2B.
- 13. The antibody according to claim 12, wherein said antibody inhibits Npt2B activity.
- 14. The monoclonal antibody according to claim 13, wherein said antibody is a humanized antibody.
- 15. A method for modulating Npt2B in a host, said method comprising:
administering an effective amount of a Npt2B modulatory agent to said host.
- 16. The method according to claim 15, wherein said modulatory agent is a small molecule.
- 17. The method according to claim 15, wherein said modulatory agent is an antibody.
- 18. A method of screening to identify Npt2B modulatory agents, said method comprising:
contacting a cell expressing functional Npt2B on its surface with a candidate agent in the presence of phosphorous anion; and determining the amount of phosporous anion uptake by said cell.
- 19. The method according to claim 18, wherein said phosphorous anion is labeled with a detectable label.
- 20. The method according to claim 19, wherein said label is isotopic.
- 21. A method of treating a host suffering from a disease condition associated with Npt2B activity, said method comprising:
administering to said host a Npt2B modulatory agent.
- 22. The method according to claim 21, wherein said Npt2B modulatory agent is an Npt2B agonist.
- 23. The method according to claim 21, wherein said Npt2B modulatory agent is an Npt2B antagonist.
- 24. The method according to claim 23, wherein said disease condition is characterized by the presence of hyperphosphatemia.
- 25. A non-human transgenic animal model capable of expressing Npt2B.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] Pursuant to 35 U.S.C. §119 (e), this application claims priority to the filing date of the U.S. Provisional Patent Application Serial No. 60/119,321 filed Feb. 9, 1999, the disclosure of which is herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60119321 |
Feb 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09499964 |
Feb 2000 |
US |
Child |
10052664 |
Jan 2002 |
US |